statement
CagriSema consists of the long-acting amylin receptor agonist cagrilintide and the GLP-1 receptor agonist semaglutide.
A statement by 界面新闻. Statements are as reported by the cited publishers — not verified by DecisionGateway.
由长效胰淀素受体激动剂卡瑞林肽和 GLP-1 受体激动剂司美格鲁肽组成
Related claims
CagriSema is a fixed-dose combination formulation.界面新闻 · statementNovo Nordisk announced that the marketing application for its new drug CagriSema (cagrilintide and semaglutide injection) for long-term weight management has been accepted by the National Medical Products Administration.诺和诺德 · statementCagriSema is injected subcutaneously once weekly.界面新闻 · statementThe two components act through different and complementary mechanisms of action, jointly acting on appetite and weight-regulation pathways.界面新闻 · statementThe 600mg continuous dosing group recorded an ACR20 value of 92.5%, demonstrating excellent efficacy in absolute terms.report author · statementA SGLang vulnerability exposed user account details in a security breach.NEAR AI · allegation